Stock AnalizEnliven Therapeutics, Inc. ELVN
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Enliven Therapeutics, Inc. (ELVN) is a healthcare company listed in the US with a market value of about $3.6B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -25%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net income | -$104M | -$89M | -$72M | -$38M | -$51M | -$41M | -$23M |
| Free cash flow | -$70M | -$73M | -$61M | -$33M | -$47M | -$37M | -$22M |
| EPS (diluted) | $-1.83 | $-1.89 | $-2.01 | $-12.05 | $-2.37 | $-3.53 | $-33.40 |
| Net margin | — | — | — | — | — | — | — |
| ROIC | -20.5% | -26.7% | -26.8% | — | — | -39.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $74.33, 52% above the current price; targets range from $69.00 to $82.00; the consensus rating is “Strong buy”; expected EPS is $-1.67 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Enliven Therapeutics pay a dividend?
Not currently.
Is Enliven Therapeutics a good stock to buy?
We do not give buy or sell advice. Enliven Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.